Search

Author/Creator Ahn, M-J

1. 1396PEfficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y). (23rd October 2018)

Authors:
Moro-Sibilot, D; Ahn, M-J; Halmos, B; Kim, D-W; Riely, G J; Shaw, A T; Yang, P-C; Lanzalone, S; Polli, A; Wilner, K D; De Castro Carpeño, J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 414PDPhase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors. (23rd October 2018)

Authors:
Cho, B C; Perets, R; Bar, J; Ahn, M-J; Kim, D-W; Yoh, K; Nagrial, A; Spigel, D R; Lee, D H; Gutierrez, M; Kotasek, D; Siddiqi, S; Chain, A; Butts, B D; Zhang, Y; Li, X; Cyrus, J; Tse, A; Altura, R A; Rasco, D
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 474O Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC. (24th November 2019)

Authors:
Cho, B C; Lee, K H; Ahn, M-J; Geater, S Lucien; Ngoc, T V; Wang, C-C; Cho, E K; Lee, J S; Sriuranpong, V; Bui, Q; Clarke, S; Kuyama, S; Nakagawa, K; Liu, F; Clemett, D; Scheuring, U; Peters, S; Rizvi, N
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 475OOverall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI). (24th November 2019)

Authors:
Wu, Y-L; Mok, T S K; Han, J-Y; Ahn, M-J; Delmonte, A; Ramalingam, S S; Kim, S-W; Shepherd, F A; Laskin, J; He, Y; Akamatsu, H; Theelen, W S M E; Su, W-C; John, T; Sebastian, M; Mann, H; Miranda, M; Laus, G; Rukazenkov, Y; Papadimitrakopoulou, V
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. 511PAURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS). (25th November 2018)

Authors:
Zhou, C; Wang, M; Cheng, Y; Chen, Y; Zhao, Y; Shi, Y-K; Ahn, M-J; Lu, Y; Shi, M; Han, J-Y; Kim, S-W; Zhang, H-L; Chen, G; Li, H; Wang, J; Wu, Y-L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 98P Results from a phase I study of MK-1308 (anti–CTLA-4) plus pembrolizumab in previously treated advanced small cell lung cancer. (15th December 2019)

Authors:
Cho, B C; Yoh, K; Bar, J; Nagrial, A; Spigel, D R; Gutierrez, M; Kim, D-W; Kotasek, D; Rasco, D; Niu, J; Satouchi, M; Ahn, M-J; Lee, D H; Maurice-Dror, C; Siddiqi, S; Li, X; Cyrus, J; Altura, R A; Perets, R
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗